## Kiwon Kim

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3776928/publications.pdf

Version: 2024-02-01

		1478505	1372567	
11	219	6	10	
papers	citations	h-index	g-index	
11	11	11	370	
all docs	docs citations	times ranked	citing authors	

#	Article	IF	CITATIONS
1	Korean Society of Nephrology hemodialysis unit accreditation report (2016–2020) and future directions. Kidney Research and Clinical Practice, 2022, , .	2.2	1
2	Trends in epidemiologic characteristics of end-stage renal disease from 2019 Korean Renal Data System (KORDS). Kidney Research and Clinical Practice, 2021, 40, 52-61.	2.2	68
3	Effect of patient solicitation on mortality among patients receiving hemodialysis in Korea Patient Preference and Adherence, 2019, Volume 13, 1073-1082.	1.8	3
4	HL156A, a novel AMP-activated protein kinase activator, is protective against peritoneal fibrosis in an in vivo and in vitro model of peritoneal fibrosis. American Journal of Physiology - Renal Physiology, 2016, 310, F342-F350.	2.7	25
5	Clinical Correlates of Mass Effect in Autosomal Dominant Polycystic Kidney Disease. PLoS ONE, 2015, 10, e0144526.	2.5	43
6	Chemotherapy in Small Cell Lung Cancer with End-Stage Renal Disease on Hemodialysis. The Ewha Medical Journal, 2014, 37, S5.	0.2	0
7	A Higher Salt Intake Leads to a Lower Rate of Adequate Blood Pressure Control. Journal of Korean Medical Science, 2014, 29, S103.	2.5	6
8	Current status and standards for establishment of hemodialysis units in Korea. Korean Journal of Internal Medicine, 2013, 28, 274.	1.7	16
9	Prevalence of Anemia and Calcium-Phosphorus Abnormalities in Hemodialysis Patients in Southwestern Seoul. Korean Journal of Medicine, 2013, 85, 378.	0.3	2
10	Pharmacokinetic Profiles of Ceftazidime after Intravenous Administration in Patients Undergoing Automated Peritoneal Dialysis. Antimicrobial Agents and Chemotherapy, 2011, 55, 2523-2527.	3.2	11
11	Could Solutions Low in Glucose Degradation Products Preserve Residual Renal Function in Incident Peritoneal Dialysis Patients? A 1-Year Multicenter Prospective Randomized Controlled Trial (Balnet) Tj ETQq1 1 (	0.78 <b>43</b> 14 r	gB <b>4</b> 4Overloc